Research Factors Predictive of Treatment Failure With Erythropoietin Beta (NeoRecormon®) in Patients With Solid Tumors Treated With Chemotherapy
- Identify factors predictive of treatment failure in patients with solid tumors treated
with epoetin beta while undergoing chemotherapy.
- Evaluate the impact of achieving target hemoglobin levels (i.e., hemoglobin > 11 g/dL)
after 8 weeks of treatment with epoetin beta.
- Evaluate changes in hemoglobin levels from baseline to after 8 weeks of treatment with
- Evaluate the tolerability of epoetin beta in these patients.
- Evaluate the quality of life of these patients.
OUTLINE: This is a multicenter study.
Patients receive epoetin beta subcutaneously once a week for ≥ 8 weeks in the absence of
disease progression or unacceptable toxicity.
Patients complete a quality-of-life questionnaire (FACT-An) at baseline and after 8 weeks of
Allocation: Non-Randomized, Primary Purpose: Supportive Care
Treatment failure (changes in hemoglobin levels)
Damien Pouessel, MD
Centre Val d'Aurelle - Paul Lamarque